Drug Interaction in Psycho-Oncology: Antidepressants and Antineoplastics

C. Miguel a E. Albuquerque b

a Psychiatry Service of Hospitals of the University of Coimbra, and b Psychiatry Unit of the Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal

Key Words
Antidepressants • Antineoplastic drugs • Drug interactions

Abstract
Background and Objectives: Although there is a growing impact of psychiatric and depressive disorders in cancer patients, literature on the idiosyncrasies of antidepressants (ADs) used in those conditions and their interactions with antineoplastic agents (ANs) is scarce. Sharing the same bio-transformation pathways enhances the risk of drug interaction between ADs and ANs, specifically when compounds are inducers, inhibitors or substrates of cytochrome P450 (CYP 450). In cancer patients, such drug interactions may result in less efficacy of the drug and/or increase of their side effects. Therefore, the choice of AD should be cautious (safe and effective) and well supported. The main purpose of this review was to analyze the individual pharmacokinetic properties of the most used ADs and ANs in order to summarize the risk of possible drug interactions between them, anticipating the consequences of their coadministration. Methods: The authors reviewed books and PubMed online articles published in the last 6 years. Results: Most of the ANs are subject to transformation by CYP 450 3A4 and their coadministration with ADs, that have inhibitory properties of this CYP isoform, such as fluoxetine, sertraline, paroxetine and fluvoxamine, may result in the loss of the AN’s efficacy or higher toxicity. Conclusion: Among the ADs, escitalopram, citalopram, venlafaxine, mirtazapine and milnacipran stand out for their weak CYP 450 inhibitory potential and their safety profile in those patients.

Introduction

Psychiatric disorders affect about half of the cancer patients [1]. Adjustment disorder is the most frequent diagnosis, followed by major depression, with prevalences going from 4 to 35% and from 3 to 36%, respectively, according to the diagnostic criteria used, the sample studied (outpatient, pre- or postsurgical), and the type and stage of cancer [2–4].

Several studies have looked at the impact of depression on cancer patients, supporting a significant relationship between depression and lower quality of life, increased perception of pain, suicidal ideas, wish for hastened death, low compliance to treatment and a worse prognosis [5–7]. This evidence was the base of several consensus conferences, guidelines, algorithms and reviews, devel-
oped with the purpose of promoting and conciliating
psychopharmacological and psychosocial treatments,
and highlighting the need of evaluating and treating de-
pression in cancer patients [2, 8, 9].
In fact, the use of antidepressants (ADs) in cancer pa-
patients has increased in the last 20–25 years [2, 10], and is
recommended in the treatment of severe to moderate ma-
jor depression [11]. Yet, the evidence does not support the
supremacy of one AD over the other or a pharmacological
treatment over a psychosocial one [11]. Nevertheless, it is
widely accepted that the choice of the AD must take into
account individual factors, such as side effects, patient’s
symptoms and preferences, the previous clinical re-

t
dorse, and coadministered drugs [11].
In cancer patients particularly, the choice of a psycho-
tropic drug is a challenge that must target ‘not to harm’.
In fact, those patients are more vulnerable to drug inter-
actions because of their physical fragilities (poor nutri-
tion, weight loss, other medical conditions, young or ad-
vanced age), multimedication and possible enzyme defi-
cit due to genetic polymorphisms or iatrogenic causes
[12]. Therefore, the choice of psychotropic drugs must be
cautious, minimizing the possible increase in adverse
side effects and the decrease in the efficacy of drugs which
are crucial to the treatment of cancer.
Both ADs and antineoplastic agents (ANs) have nar-
row therapeutic indices and consequently, small var-
iations in their plasmatic concentrations may result
in subtherapeutic or toxic effects [13]. ANs and ADs
may interact by pharmacokinetic or pharmacodynamic
mechanisms which are independent of the pharmacolog-
ic properties responsible for their therapeutic efficac-
(i.e. mechanism of action and ‘class effect’) [14].
Although pharmacokinetic drug interactions between
ADs and ANs may result in changes in absorption, dis-
tribution or elimination of one of them (when subordi-
nated to the effect of the other), those relevant to clinical
practice are attributed mostly to induction or inhibition
of cytochrome P450 (CYP 450) occurring in phase I bio-
transformation [13, 15–17]. In fact, most ANs and ADs
are metabolized by CYP 450 enzymes, and it is precisely
this sharing of biotransformation pathways that carries a
high potential of interaction resulting in an increase or
decrease in plasmatic concentrations [13, 15].
On the other hand, pharmacodynamic drug inter-
actions occur when the concomitant use of two drugs
modifies their pharmacological effect and does not
change their pharmacokinetics (plasmatic concentra-
tion sustained) [12, 13]. Those reactions may be additive,
synergic or antagonistic, and are usually predicted ac-
cording to the mechanism of action of each agent on the
target receptor or enzyme [14]. In fact, in the last decade,
in vitro studies have been used to evaluate, understand
and anticipate the risk of drug interactions [14]. In spite
of the recognized limitations, this emerging knowledge
and evidence is of great value in building a descriptive
scientific model of the pharmacokinetic and pharma-
dynamic behavior of these drugs, allowing to anticipate
and to prevent potentially adverse drug interactions
[14].
In psycho-oncology, except for the research on the si-
multaneous use of ADs and tamoxifen (TMX) in breast
cancer patients [18, 19], the literature is scarce on reviews
or research addressing the drug interactions between
ANs and ADs and their clinical consequences. Recently,
in Singapore, Oncorx has been developed [13]. It is a
computer database, still with restricted access, which fa-
cilitates the knowledge of probable drug interactions be-
tween the main groups of ADs and ANs, used as mono-
therapy or chemotherapy protocols, based on known
pharmacokinetic parameters [13].
Recognizing the importance of this issue, the authors
propose to analyze the individual pharmacokinetic pro-
file of the most commonly used ADs and ANs, and point-
ed out possible interactions between these two groups of
drugs, emphasizing the risk of toxicity from antineoplas-
tic activity.

Method
In this review, papers published after 2005, namely specific
books about drug interactions in psychiatry and psychophar-
cology and online papers were considered. PubMed articles
were retrieved through the association of the following terms: anti-
depressants, tricyclic antidepressants, depression, anticancer drugs,
antineoplastic drugs, tamoxifen and oncology; with the words:
metabolism, CYP 450 inhibition and drug interactions. More-
over, for a specific drug (x) whose biotransformation pathway was
not clarified by the previous method, an individual research was
performed in Google (‘x metabolism’). Only two papers aged 12
and 13 years were chosen because of their value to the realization
of this review.

Metabolism of Drugs: CYP 450
Among the 4 major phases which are part of the phar-
cokinetic process – absorption, distribution, metabo-
lization and elimination – biotransformation is the one
that deserves to be highlighted concerning drug interac-
tions [14]. In this phase, the following possibilities must
be considered: (1) the ‘parent compound’ (pro-drug) needs to be metabolized into an active metabolite (ActiveMet) to have a therapeutic effect; (2) the ‘parent compound’ is active and after metabolism, ActiveMet(s) are formed but with different pharmacologic properties which are usually responsible for side effects; (3) the ‘parent compound’ is active and deactivated after metabolism [20].

Drug biotransformation depends on 2 phases: phase I (oxidation), which covers redox or hydrolytic reactions responsible for the conversion of lipophilic drugs into more polar metabolites (e.g. alcohols, phenols and carboxylic acids), and phase II reactions of conjugation forming products such as glucuronides and sulfates, readily excreted in urine [14].

Most phase I reactions are catalyzed by CYP 450 localized mostly in the liver. CYPs are a group of about 30 oxidative heterogeneous isoenzymes classified in families by numbers (CYP 1, CYP 2 and CYP 3) and in subfamilies by a capital letter, based on the shared amino acid sequences. In humans, the CYP P450 isomers most involved in the metabolism of drugs are 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5 and 3A7 [14]. The CYP 2D6 and CYP 3A4 isomers are responsible for metabolizing most psychotropics [12] and they can be subject to induction or inhibition by other drugs or substances.

The evidence shows that the activity of a pro-drug, which is transformed into an ActiveMet, is increased in the presence of an inducer, being the contrary true for those being inactivated after metabolism. However, when a drug interaction changes the concentration of a ‘parent drug’ and its metabolites, and when both are equivalent in efficacy and safety, the inhibition or induction has little therapeutic implications [21].

Besides coadministered drugs, also the patient’s physiologic status (age, gender, and comorbidity) and his/her genetic polymorphisms may be responsible for different drug-metabolizing enzyme activity [21]. It is estimated that genetics may explain 20–95% of variability in the therapeutic response and toxicity [21, 22].

**The Particular Case of TMX**

Among the ANs, TMX is the one more extensively studied for drug interactions with ADs. TMX is a selective modulator of estrogen receptors [12]. In women with breast cancer and at the initial stage, the use of TMX has been associated with a reduced risk of recurrence at about 1/2 and death risk by breast cancer at about 1/3 [12]. TMX is converted to endoxifen, its ActiveMet, by the most polymorphic and well-studied gene of the CYP 450 system: CYP 2D6 [12]. More than 80 different major alleles were identified, many of which are responsible for increased or reduced activity of CYP 2D6 [15, 23–26]. Thus, based on the genotype, individuals can be divided into weak, intermediate, extensive or very extensive metabolizers [15]. The CYP 2D6 lack of activity compromises TMX efficacy by reducing its bioactivation to endoxifen [15, 23–26].

Several studies have shown that drugs that inhibit CYP 2D6 can reduce the clinical benefit of TMX [27, 28]. SSRIs inhibit, to varying degrees, CYP 2D6 [19] (table 1). Pharmacological inhibition of CYP 2D6 has also been associated with worse breast cancer prognosis. This observation is consistent with the critical role of CYP 2D6 in the metabolic activation of TMX and puts in evidence a drug interaction that can and should be avoided.

**Interactions between ADs and Cytostatics**

Drug interactions can result in clinically significant changes in pharmacokinetics and/or pharmacodynamics of ANs altering their therapeutic efficacy and toxicity. Concerning ANs, at present, the majority of information available comes from animal experiments or in vitro tests [21]. Despite these limitations, research has provided valuable information on the pharmacokinetics of either ADs or ANs, allowing the integration of these data to predict possible drug interactions between these two categories of drugs.

Recent studies focusing on the inhibitory properties of tricyclic ADs are scarce. However, there is some evidence on their moderate to high inhibitory potential on CYP 2C19 and CYP 2D6 isoenzymes [29, 30]. Much more information is available about SSRIs. Besides markedly inhibiting CYP 2D6, fluoxetine inhibits moderately CYP 2C19 and 2C9 isoenzymes [14, 19, 31]. Sertraline can also cause moderate inhibition of CYP 2C19 [32] and fluvoxamine is a strong inhibitor of CYP 1A2, 2C9 and 2C19 isoenzymes [14, 31]. As for paroxetine, its inhibitory potential is high for both CYP 2D6 and 2B6 [14, 31]. All these drugs also inhibit, to a mild degree, CYP 3A4 isoenzyme [14, 19, 31, 32].

Citalopram, escitalopram, venlafaxine and mirtazapine are among the ADs whose inhibitory potential is smaller [14, 31]. Milnacipran stands out for minimal he-
patic metabolism (limited to conjugation with glucuronic acid) being its involvement in pharmacokinetic intermediate metabolizers [33–35] unlikely.

Regarding the potential pharmacokinetic drug interactions between ANs and ADs and particularly regarding the risk of toxicity and loss of effectiveness of ANs, the combined analysis of the AD pharmacokinetic data and the known evidences about AN metabolization (table 2) support the following considerations.

(1) Altretamine and lomustine are subject to extensive hepatic metabolization with the generation of ActiveMet [36]. The isoenzymes of CYP 450 involved in the biotransformation of these ANs are still unknown [36]. However, with fluoxetine, fluvoxamine and paroxetine, moderate to powerful inhibitors of multiple isoenzymes of CYP 450 [14, 31], the reduced effectiveness of these ANs, when co-administered with these ADs, is foreseeable.

(2) The evidence based on animal studies does not suggest that busulfan and chlorambucil are metabolized by the system CYP 450 [36]. Regarding estramustine, mechlorethamine, melphalan, temozolomide, 5-fluorouracil, gemcitabine, mercaptopurine, thioguanine, cisplatin, carboplatin, oxaliplatin, daunorubcin, doxorubcin, epirubicin and vorinostat, to date, there is no evidence of the involvement of the system CYP 450 in the metabolization of these ANs, suggesting that in these cases drug interaction with ADs is rare [36].

(3) Cyclophosphamide and procarbazine are metabolized by CYP 2B6 to ActiveMets [36]. The concomitant use of an inhibitor of CYP 2B6 (e.g. paroxetine to a greater degree and fluoxetine, sertraline, fluvoxamine and buproprion to a lesser degree [14, 31]) can reduce the effectiveness of these ANs. In the particular case of cyclophosphamide, which is subject to metabolization by CYP 2C19 generating its ActiveMet, the CYP 2C19 inhibitors (e.g. sertraline [32], fluoxetine [14, 31], fluvoxamine [14, 31] and tricyclic ADs [35]) can also reduce its effectiveness.

On the other hand, the biotransformation of cyclophosphamide via CYP 3A4 leads to the formation of inactive metabolites. Therefore, by the use of CYP 3A4 inhibitors more active drug may be available (increased efficacy/toxicity ratio) and the coadministration with a CYP 3A4 inducer can be translated into higher neurotoxicity [36]. Procarbazine is subject, to a lesser extent, to metabolism in CYP 1A with the formation of ActiveMet; therefore, using this isoenzyme’s inhibitors (e.g. fluvoxamine [14]) can also reduce the effectiveness of this AN [29]. The same applies to dacarbazine whose route of biotransformation matches that of procarbazine [36].

(4) Ifosfamide, thioreta, toremifene and sunitinib are metabolized by CYP 3A4 in ActiveMet [36]. The inhibitors of this isoenzyme (i.e. fluoxetine, sertraline, paroxetine and fluvoxamine, even with slight inhibitory potential [14]) may impair the activation of the ANs compromising its therapeutic effect.

Docetaxel and paclitaxel are also metabolized by CYP 3A4. For these ANs, the use of a CYP 3A4 inhibitor may increase the plasma concentration of taxanes causing increased toxicity (e.g. myelosuppression, constitutional symptoms and peripheral neuropathy) [36]. The same occurs with the other ANs in the antimicrotubules category (vinblastine, vincristine, vindesine, vinorelbine), corticosteroids, etoposide, irinotecan and sorafenib whose overlap use with CYP 3A4 inhibitors can increase toxicity, and with CYP 3A4 inducers reduce efficacy [36]. In the case

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Inhibition of CYP 2D6</th>
<th>Advice based on evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venlafaxine</td>
<td>minimum</td>
<td>The safest choice with TMX</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td></td>
<td>Direct studies are lacking with TMX</td>
</tr>
<tr>
<td>Citalopram, escitalopram</td>
<td>slight</td>
<td>Secondary choices if previous are not viable options</td>
</tr>
<tr>
<td>Duloxetine, sertraline, fluvoxamine</td>
<td>moderate</td>
<td>Only citalopram or sertraline were studied directly with TMX, so the risk of decreasing endoxifen must be weighed against the benefits of these ADs</td>
</tr>
<tr>
<td>Paroxetine, fluoxetine, buproprion</td>
<td>strong</td>
<td>Avoid to combine with TMX</td>
</tr>
</tbody>
</table>

Adapted from Desmarais and Looper [19].

Table 1. Choice among ADs in patients with a history of breast cancer on therapy with TMX
### Table 2. Metabolism of ANs categorized by major pharmacological classes

<table>
<thead>
<tr>
<th>Antineoplastic agents</th>
<th>Metabolism</th>
<th>Probable drug interaction with INDs or INBs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkylating agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altretamine</td>
<td>Hepatic oxidation → (ActiveMet)</td>
<td>IND 2B6 may ↑ ActiveMet; INB 2B6 ↓ D efficacy; IND 3A4 can ↑ neurotoxicity, INB 3A4 may provide more active D (↑ Efficacy/toxicity)</td>
</tr>
<tr>
<td>Busulfan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorambucil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>CYP 2B6 &gt; 2C19 (ActiveMet); CYP3A4 (ActiveMet)</td>
<td>INB CYP 1A2 and 2E1 may ↓ ActiveMet</td>
</tr>
<tr>
<td>Dacarbazine</td>
<td>CYP 1A2 &gt; 2E1 (ActiveMet is a methylated DNA)</td>
<td>CYP3A4 IND may ↓ D activation and generated more metabolites, with neurotoxic potential; CYP 3A4 INB ↓ D activation and its efficacy</td>
</tr>
<tr>
<td>Estramustine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lomustine</td>
<td>Extensive hepatic oxidation → (ActiveMet)</td>
<td>Potential interaction with CYP 450 INB (↑ pro-D, ↓ efficacy and ↑ toxicity)</td>
</tr>
<tr>
<td>Mechlorethamine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melphalan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procarbazine</td>
<td>CYP 2B6 &gt; 1 A (ActiveMet)</td>
<td>CYP 2B6 or CYP 1A INB may ↓ D efficacy</td>
</tr>
<tr>
<td>Thiotepa</td>
<td>CYP 3A4 &gt; 2B6 (ActiveMet)</td>
<td>3A4 IND may ↑ ActiveMet, INB may ↓ D efficacy</td>
</tr>
<tr>
<td>Temozolomide</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antimetabolites</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capecitabine</td>
<td>5-Fluorouracil Pro-D CYP 2C9 INB potential</td>
<td>Potential to ↑ CYP 2C9 substrate concentrations</td>
</tr>
<tr>
<td>Fludarabine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemcitabine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Hepatic metabolism →</td>
<td></td>
</tr>
<tr>
<td>Thioguanine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antimicrotubules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Docetaxel</td>
<td>CYP 3A4</td>
<td>CYP 3A4 INB may ↑ taxanes (myelosuppression and peripheral neutropenia); CYP 3A4 IND may ↓ taxanes;</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>CYP 2C8 &gt; CYP3A4</td>
<td>CYP3A4 INB may ↑ paclitaxel (myelosuppression and peripheral neutropenia)</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>CYP 3A4</td>
<td>Probable ↑ with CYP 3A4 INB (myelosuppression and peripheral neutropenia) and ↓ with IND</td>
</tr>
<tr>
<td>Vincristine, vindesine, vinorelbine</td>
<td>CYP 2D6 INB potential</td>
<td></td>
</tr>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>CYP 3A4 (InactiveMet)</td>
<td>Toxicity risk with CYP 3A4 INB and ↓ efficacy with CYP 3A4 IND</td>
</tr>
<tr>
<td>Methylprednisolone, prednisolone, prednisone</td>
<td>Dexamethasone is a CYP 3A4 IND</td>
<td></td>
</tr>
<tr>
<td><strong>Hormone agonists/antagonists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anastrazole</td>
<td>(CYP 3A4 is possible)</td>
<td>(CYP 3A4 is possible)</td>
</tr>
<tr>
<td>Exemestane</td>
<td>CYP 3A4 (InactiveMet)</td>
<td>May ↑ with CYP 3A4 INB; CYP3A4 IND may ↓ efficacy</td>
</tr>
<tr>
<td>Letrozole</td>
<td>CYP 2 A6 e CYP 3A4 (MetInactivo); CYP 2 A6 and 2C19 INB</td>
<td>May ↑ with CYP 3A4 INB; CYP3A4 IND may ↓ efficacy</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>CYP 2D6 (ActiveMet) CYP 3A4 INB</td>
<td>CYP2D6 INB may ↓ efficacy; CYP 3A4 IND may ↑ risk of side effects (e.g. hot flushes, nausea, vomiting)</td>
</tr>
<tr>
<td>Toremifene</td>
<td>CYP 3A4 (ActiveMet)</td>
<td>CYP 3A4 INB may ↓ efficacy</td>
</tr>
<tr>
<td><strong>Platinum compounds</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cisplatin, carboplatin, oxaliplatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Topoisomerase inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daunorubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>(CYP 3A4 is possible)</td>
<td>May ↑ with CYP 3A4 INB (↑ ✗ myelosuppression, mucositis)</td>
</tr>
<tr>
<td>Epirubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>CYP 3A4 &gt; CYP 2E1, 1A2</td>
<td>3A4 INB may ↑ formation of SN-38 (↑ ✗ myelosuppression)</td>
</tr>
<tr>
<td>Idarubicin</td>
<td></td>
<td>3A4 INB may ↑ conversion of SN-38 to InactiveMet (↓ Efficacy)</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>CYP 3A4 (ActiveMet)</td>
<td></td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topotecano</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Antidepressants and Antineoplastics**
of exemestane and letrozole, the likely toxicity with the use of CYP 3A4 inhibitors is translated into myalgia, constitutional symptoms, peripheral edema and hot flushes [29]. Under these conditions, regarding imatinib, the most prominent adverse symptoms are the weight gain, nausea, vomiting and neutropenia [36]. The toxicity of dasatinib can also increase with the coadministration of CYP 3A4 inhibitors [36].

**Conclusion**

In oncological patients, the AD choice is a swing where the profile of side effects and pharmacokinetics should be well weighed. Drug interactions between ADs and ANs can compromise the effectiveness of ANs and increase their toxicity with obvious prognostic implications. The information available about the metabolization of ADs and ANs with emphasis on the CYP 450 system facilitates drug interaction prediction, which could be avoided if undesirable.

The pharmacokinetic drug interactions with ADs are unlikely with busulfan, chlorambucil, estramustine, mechlorethamine, melphalan, temozolomide, 5-fluorouracil, gemcitabine, mercaptopurine, thioguanine, cisplatin, carboplatin, oxaliplatin, daunorubicin, doxorubicin, epirubicin and vorinostat. Among the remaining ANs considered here, the risk of loss of efficacy or increased toxicity, when coadministered with certain ADs, is a possibility. Venlafaxine, mirtazapine, citalopram and escitalopram are small inhibitors of CYP 2D6, therefore being a safe choice when using TMX. Most of the other ANs subjected to metabolization by CYP 450 3A4 should be used with caution concomitantly with inhibitors of this isozyme such as fluoxetine, sertraline, paroxetine and fluvoxamine. Escitalopram, citalopram, venlafaxine, mirtazapine and milnacipram are ADs with minimal CYP 450 inhibitory potential and are therefore safer in these patients.

**Limitations of This Review**

Regarding drug interactions between ANs and ADs, neither pharmacodynamic phenomena nor hepatic conjugation reactions have been considered. The results proposed here are from the integration of evidence known about the individual pharmacokinetics of the ADs and ANs. These are, however, assumptions that need additional support. In fact, with the exception of extended research on TMX, the literature lacks evidence on the impact of different ADs in plasma concentrations of ANs (and its metabolites) and its anticancer efficacy and toxicity.
References


